跳至主要内容
临床试验/EUCTR2011-001674-25-ES
EUCTR2011-001674-25-ES进行中(未招募)1 期

Evaluation of the efficacy of sildenafil on the functional capacity of patients with heart failure with preserved ejection fraction. A randomized, double blind, parallel group and placebo-controlled clinical trial. - SILICCO

Francisco J. González Vílchez0 个研究点目标入组 100 人开始时间: 2012年3月28日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Age > 18 years.
  • 2. Previous diagnosis of heart failure by any of the following:
  • - Criteria of Framingham.
  • - Hospitalization for decompensated heart failure.
  • - Long-term treatment with a loop diuretic and chronic diastolic dysfunction (left atrial enlargement by echocardiography).
  • 3. Current symptoms with functional class (NYHA) II-IV.
  • 4. Left ventricular ejection fraction > 50% by echocardiography whinthin the previous 3 months before study entry.
  • 5. Receiving stable medical therapy in the 30 days before study entry, as determined by no addition or removal of angiotensin converting enzyme inhibitor (ACE), angiotensin receptor blocker (ARB), beta-blockers, or calcium channel blockers (CCB) and no change in dosage of ACE, ARBs, beta-blockers, or CCBs of more than 100%.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 70

排除标准

  • 1. Has a non-cardiac condition that prevents the subject from exercise testing or from walking in a hallway.
  • 2. Non-cardiac life expectancy < 1 year.
  • 3. Current or anticipated future need for nitrate therapy.
  • 4. Any valvular, pericardial o cardiomyopathy with specific therapy requirements.
  • 5. Acute coronary syndrome o coronary revascularization in the previous 6 months or expected need of coronary revascularization in the year after study entry.
  • 6. Any non-cardiac condition known to be associated with dyspnea (morbid obesity [Body mass index > 35 Kg/m2] or lung disease requiring oxygen or esteroids or FEV1 < 50% predicted or Epworth Sleepiness Scale > 20).
  • 7. Resting blood pressure < 110 / 40 mmHg or > 180 /100.
  • 8. Resting heart rate > 100 bpm.
  • 9. History of ejection fraction < 50%.
  • 10. Hb < 10 g/dL, severe renal disease (estimated glomerular filtration rate < 20 ml/min/1.73m2 g) or severe hepatic disease (aspartate aminotransferase level > 3 times the normal limit, alkaline phosphatase or bilirubin > 2 times the normal limit).
  • 11. Pregnant or not using an effective form of contraception.
  • 12. Taking nitrates, alpha antagonists, cytochrome P450 3A4 inhibitors/inducers, nicorandil, ranolazine or molsidain.
  • 13. Retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy, or unexplained visual disturbance.
  • 14. Sickle cell anemia, multiple myeloma, leukemia, or penile deformities that increase the risk for priapism (e.g., angulation, cavernosal fibrosis, Peyronie's disease).
  • 15. Severe cardiac ischemia in scintigraphy or echocardiography.
  • 16. Primary pulmonary arteriopathy.
  • 17. Inability or unwillingness of individual to give written informed consent.
  • 18. Participation in a clinical trial within the 6 months prior to the present study.
  • 19. History of allergy or intolerance to Sildenafil or other 5-Phosphodiesterase inhibitor.

研究者

发起方
Francisco J. González Vílchez

相似试验